Vinay Mathew Thomas
@vinay_oncHusband | Dad | Heme/onc fellow @huntsmancancer | GU Oncology @Huntsman_GU | Prior Chief Medical Resident and Internal Medicine Resident @UConnIM
Similar User
@ggebraelmd
@AJangMD
@maughanonc
@AmandaNizamMD
@ADESAIONCMD
@KMittalmd
@nerealiamd
@ASridharMD
@DMakrakisMD
@MeghanaSinghMD
@umangtalking
@OncHahn
@YuWeiChenMD
@GliceidaGalarza
@AbhiTrip87
The diagnosis of neuroendocrine prostate cancer is often challenging. Here is our perspective @CCR_AACR on the pathologic work-up of NEPC. With #MHaffner @surrealistNYC @drmehrarohit @LotanLab @MarkARubin1 and many other great colleagues @PCF_Science pubmed.ncbi.nlm.nih.gov/39589343/
Just in @JournalCancer 👉Consensus statement from 2024 United States #ProstateCancer Conference (USPCC)👉Management of PSA recurrence, mHSPC, mCRPC, Rx with RLTs, PARPi & more (US perspective)👉open access👉 bit.ly/3ZzWRfu @PCF_Science @urotoday @OncoAlert @AlanBryce9
Very happy to share the manuscript from the 2024 United States Prostate Cancer Consensus Conference. Our goal with this is to address the many common clinical conundrums that occur daily in prostate cancer clinics but fall outside the areas covered by level 1 evidence. The US…
Very happy to share the manuscript from the 2024 United States Prostate Cancer Consensus Conference. Our goal with this is to address the many common clinical conundrums that occur daily in prostate cancer clinics but fall outside the areas covered by level 1 evidence. The US…
BRCA2 germline variants show no significant impact on survival in high-risk localized or metastatic prostate cancer, except in de novo metastatic cases. 🧬🧬Other DNA repair genes lacked precision due to rarity. #ProstateCancer #Genetics #Oncology #research @OncoAlert…
Clinically critical Q. Twice-daily prednisone (2*5 mg) significantly reduces the risk of hypertension and hypokalemia in abiraterone-treated prostate cancer patients, without impacting BMI or blood sugar. @TomFlaigMD #ProstateCancer #Oncology #CancerResearch @OncoAlert @ASCO…
Packed room @SWOG GU committee 2024 fall meeting, with opening remarks by @slernerbcmedu1 👉Congrats @umangtalking @huntsmancancer for receiving @SWOG Dr. Vogelzang scholar award 👉consider supporting @HopeFoundation for Dr. Vogelzang fund👉 bit.ly/4dSbE8U @PrimoLaraMD
Super relevant data @NEJM Results after Four Years of Screening for Prostate Cancer with PSA and MRI Key findings: Four-year results show MRI-targeted prostate cancer screening reduces overdiagnosis by 57%, cuts biopsies by up to 74%, and maintains effectiveness in detecting…
A gripping grand round “Gut Bacteria & Cancer: Friend and Foe?” by super investigator @montypal Fascinating to learn about microbiome potential, ways to modulate it including exercise @NeliMUlrich @neerajaiims and his IITs with CBM588 & camu-camu
Front row to watch @montypal ‘s terrific internal medicine grand round on gut bacteria and cancer! @neerajaiims @Huntsman_GU @umangtalking @ziremozay @ggebraelmd @UofUInternalMed @NeliMUlrich @maughanonc @nsayeghmd
What an honor to give the #Quagliana Endowed Lectureship at @UUtah/@UofUInternalMed! Many thanks to @neerajaiims for the invitation. Beyond the lecture, was delighted to sit in with his research team (@umangtalking @ggebraelmd @maughanonc @vinay_onc @chadihc98 @ziremozay et al)…
Just in👉bit.ly/3AMRBec Real world claims analysis of 10 AEs in #mCSPC. AE rates⬆️over time across Rx groups. Most AE rates with ADT+ARPIs were comparable to ADT+NSAA & ADT alone. ADT+docetaxel had⬆️rates of 7 AEs. Sexual function AE didn't differ between Rx. @OncoAlert
Congrats @DrChoueiri @tompowles1 @AlbigesL @brian_rini and the team for this stupendous work leading to approval of belzutifan for our patients with mccRCC #kidneycancer @KidneyCancer @kidneycan
#prostatecancer a 🧵 I’ve been told “at least you got the good cancer to get” so I thought I’d do a 🧵 about what a stage 4 incurable cancer is really like and the impact on life. Let’s start with the treatment for it which the mainstay of is removal of male hormone 1/
How to manage side effects (AEs) of enfortumab vedotin in patients with #bladdercancer 👉safety correlates with drug exposure, dose reduction is an effective way to manage AEs👇 Excellent talk by @sandysrimd at the #WorldGU24 @GUconference, @urotoday @OncoAlert @BladderCancerUS
Just in👉bit.ly/3Wygodg One of the largest real world studies evaluating trt trends in #nmCRPC found underutilization of NHT even 2 years after approval. ADT and ADT+NSAA remained most common trt. @PCFnews @urotoday @OncoAlert #prostatecancer
Another stellar talk by @BraunMDPhD in #Worldgu24 @GUconference 👉How to diagnose RCC #kidneycancer pts with residual disease after surgery? 👉liquid epigenomic profiling, CTCs (shoutout to the great @JoshLangMD ), Kim-1 and more👇 @kidneycan @urotoday @OncoAlert
Congrats for really great work on this important issue @chadihc98 @ggebraelmd @nsayeghmd @vinay_onc @umangtalking @maughanonc @neerajaiims @huntsmancancer @OncoAlert @urotoday @SWOG @montypal @DrChoueiri @FaltasLab @HsiehLab @UUtah @PCFnews @BladderCancerUS @WorldBladderCan
Happy to share our recently published work in @JAMANetworkOpen co-lead w/ @YeonjungJoHCI showing ⬇️ NGS testing rates in pts w/ metastatic prostate & urothelial cancers👉Grateful for terrific mentorship from @umangtalking @neerajaiims & team @ggebraelmd @urotoday @OncoAlert
Just in @JAMANetworkOpen 👉 Unacceptablely low rates of NGS testing in metastatic #ProstateCancer #bladdercancer in real world pts (worse in Black & Hispanic pts)@flatironhealth👇Proud of our postdoc, Chadi @chadihc98 , Yeonjung @yeonjungjohci, George @ggebraelmd & team👇…
Heartiest congratulations to @neerajaiims and @AdrianaMColetta for @huntsmancancer Collaborative Award for RO1 grant 👉 randomized trial of creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression
Biomarker data from CLEAR (len/pembro vs sunitinib) in 1st line RCC. Within arm analysis didn’t show discriminatory signature for Len/pem unlike 426 & IM151. Angiogenic signatures & MYC alterations ⬆️ sunitinib as expected. Molecular clusters/DNA/PD-L1 also struggled. #ASCO24
Fantastic presentation by Dr. @shilpaonc 👉pts reported outcomes from ph3 EV-302 trial @ASCO #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. @tompowles1 @BladderCancerUS @OncoAlert @umangtalking
United States Trends
- 1. Josh Allen 32,6 B posts
- 2. Lions 97,6 B posts
- 3. Lions 97,6 B posts
- 4. Dan Campbell 6.872 posts
- 5. $EMT 3.927 posts
- 6. Colts 30,2 B posts
- 7. Steelers 67,2 B posts
- 8. Eagles 85,2 B posts
- 9. #EarthMeta 1.738 posts
- 10. #iskalovefsocietykod 2.617 posts
- 11. Broncos 36,6 B posts
- 12. Chargers 22,5 B posts
- 13. Jalen 35,3 B posts
- 14. #OnePride 10,7 B posts
- 15. Najee 5.907 posts
- 16. Tomlin 8.220 posts
- 17. Buffalo 21,9 B posts
- 18. Jonathan Taylor 3.683 posts
- 19. Bo Nix 6.167 posts
- 20. Mike Evans 5.742 posts
Who to follow
-
Georges Gebrael
@ggebraelmd -
Albert Jang, MD
@AJangMD -
Benjamin L Maughan
@maughanonc -
Amanda Nizam, MD
@AmandaNizamMD -
Arpita Desai
@ADESAIONCMD -
KMittaloncMD
@KMittalmd -
Nerea Lopetegui-Lia, MD
@nerealiamd -
Arthi Sridhar
@ASridharMD -
Dimitrios (Dimitri) Makrakis
@DMakrakisMD -
Meghana Singh
@MeghanaSinghMD -
Umang Swami
@umangtalking -
Andy Hahn
@OncHahn -
Yu-Wei Chen, MD, MS
@YuWeiChenMD -
Gliceida Galarza, MD
@GliceidaGalarza -
Abhishek Tripathi
@AbhiTrip87
Something went wrong.
Something went wrong.